Nitric oxide-mediated promotion of mammary tumour cell migration requires sequential activation of nitric oxide synthase, guanylate cyclase and mitogen-activated protein kinase

International Journal of Cancer

Volumn 106, Issue 4, 2003, Pages 496-504

  Jadeski, Lorraine C ^a   Chakraborty, Chandan ^a   Lala, Peeyush K ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Cell migration; Guanylate cyclase; Mammary tumour; MAP kinase; Nitric oxide

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 8 BROMO CYCLIC GMP; ARGININE; CYCLIC GMP DERIVATIVE; GUANYLATE CYCLASE; GUANYLATE CYCLASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BREAST TUMOR; CANCER GROWTH; CANCER INVASION; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL MOVEMENT; CYCLIC GMP; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; GUANYLATE CYCLASE; IMMUNOENZYME TECHNIQUES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; TUMOR CELLS, CULTURED;

EID: 0042093606     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11268     Document Type: Article

References (51)

1. Moncada S, Higgs EA The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
2. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994;298:249-58.
3. Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K, Emson PC, Moncada S. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 1995;92:4392-6.
4. Lala PK, Orucevic A. Role of nitric oxide in tumor progression: lessons from experimental tumors. Cancer Metast Rev 1998;17:91-106.
5. Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and turnout progression. Lancet Oncol 2001;3:149-56.
6. Orucevic A, Bechberger J, Green AM, Shapiro RA, Billiar TR, Lala PK. Nitric oxide production by murine mammary adenocarcinoma cells promotes tumor cell invasiveness. Int J Cancer 1999;81:889-96.
7. G-Nitro-L-Arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol 1999;155:1381-90.
8. Jadeski LC, Hum KO, Chakraborty C, Lala PK. Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer 2000;86:30-9.
9. Klemke RL; Cal S, Giannini AL, Gallagher PJ, De Lanerille P, Cheresh DA. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 1997;137:481-92.
10. Brodt P, Parhar R, Sankar P, Lala PK. Studies on clonal heterogeneity in two spontaneously metastasizing mammary carcinomas of recent origin. Int J Cancer 1985;35:265-73.
11. Lala PK, Parhar RS, Singh P. Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumour-bearing mice and prevents tumour metastasis. Cell Immunol 1986;99:108-18.
12. Lala PK, Parhar RS. Eradication of spontaneous and experimental adenocarcinoma metastases with chronic indomethacin and intermittent IL-2 therapy. Int J Cancer 1993;54:677-84.
13. Gleeson LM, Chakraborty C, McKinnon T, Lala PK. Insulin-like growth factor-binding protein I stimulates human trophoblast migration by signaling through alpha 5 beta 1 integrin via mitogen-activated protein kinase pathway. J Clin Endocrinol Metab 2001;86:2484-93.
14. Brown C, Pan X, Hassid A. Nitric oxide and C-type atrial natriuretic peptide stimulate primary aortic smooth muscle cell migration via a cGMP-dependent mechanism-relationship to microfilament dissociation and altered cell morphology. Circ Res 1999;84:655-67.
15. Bussolino F, DiRenzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629-41.
16. Koyama N, Koshikawa T, Morisaki N, Saito Y, Yoshida S. Bifunctional effects of transforming growth factor-β on migration of cultured rat aortic smooth muscle cells. Biochem Biophys Res Comm 1990;169:725-9.
17. Merwin JR, Newman W, Beall LD, Tucker, A, Madri J. Vascular cells respond differentially to transforming growth factors β1 and β2 in vitro. Am J Pathol 1991;138:37-51.
18. Noiri E, Hu Y, Bahou WF, Keese CR, Giaever I, Goligorsky MS. Permissive role of nitric oxide in endothelin-induced migration of endothelial cells. J Biol Chem 1997:272:1747-52.
19. Noiri E, Lee E, Testa J, Quigley J, Colflesh D, Keese CR, Giaever I, Goligorski MS. Podokinesis in endothelial cell migration: role of nitric oxide. Am J Physiol 1998;274:C236-C44.
20. Ziche M, Morbidelli L, Masini C, Amerini S, Granger H, Maggi C, Geppetti P, Ledda F. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994;94:2036-44.
21. Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not fibroblast growth factor-induced angiogenesis. J Clin Invest 1997;99:2625-34.
22. Noiri E, Peresleni T, Srivastava N, Weber P, Bahou WF, Peunova N, Goligorsky MS. Nitric oxide is necessary for a switch from stationary to locomoting phenotype in epithelial cells. Am J Physiol 1996;270:C794-C802.
23. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathology and pharmacology. Pharmacol Rev 1991;43:109-42.
24. 2+ current: involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activator. J Biol Chem 1993;268:26286-95.
25. VanUffelen Be de Koster BM, van den Broek PJA, VanSteveninck J, Elferink JGR. Modulation of neutrophil migration by exogenous gaseous nitric oxide. J Leukoc Biol 1996;60:94-100.
26. Schmidt HHHW. NO, CO and OH, endogenous soluble guanylate cyclase-activating factors. FEBS Lett 1992;307:102-7.
27. Vila-Petroff MG, Younes A, Egan J, Kakatta EG, Sollot SJ. Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circ Res 1999;84:1020-31.
28. Murad F. The 1996 Albert Lasker Medical Research Awards. Signal transduction using nitric oxide and cyclic guanosine monophosphate. JAMA 1996;276:1189-92.
29. Pham N, Cheglakov I, Koch CA, de Hoog CL, Moran MF, Rotin D. The guanosine nucleotide exchange factor CNrasGEF activates ras in response to cAMP and cGMP. Curr Biol 2000;10:555-8.
30. Scott JD. Cyclic nucleotide-dependent protein kinases. Pharmacol Ther 1991;50:123-45.
31. Goetze S, Kintscher U, Kim S, Meehan WP, Kaneshiro K, Collins AR, Fleck E, Hsueh WA, Law RE. Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration. J Cardiovasc Pharmacol 2001:38:909-21.
32. Yamboliev IA, Gerthoffer WT. Modulatory role of ERK MAPK-caldesmon pathway in PDGF-stimulated migration of cultured pulmonary artery SMCs. Am J Physiol Cell Physiol 2001;280:1680-8.
33. Cho SY, Klempke RL. Extracellular-regulated kinase activation and CAS/Crk coupling regulate cell migration and suppress apoptosis during invasion of the extracellular matrix. J Cell Biol 2000;149:223-36.
34. Cai W, Rook SL, Jiang ZY, Takahara N, Aiello LP. Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth. Invest Ophthalmol 2000;41:1885-93.
35. Hauck CR, Sieg DJ, Hsia DA, Loftus JC, Gaarde WA, Monia PP, Schlaepfer DD. Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells. Cancer Res 2001;61:7079-90.
36. Nguyen DH, Catling AD, Webb DJ, Sankovic M, Walker LA, Somylo AV, Weber MJ, Gonias SL. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J Cell Biol 1999;146:149-64.
37. 1/2 activation in postcapillary endothelium. J BioI Chem 1998;273:4220-6.
38. Thomsen LL, Lawton FG, Knowles R, Beesley JE, Riveros-Moreno V, Moncada S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res 1994;54:1352-4.
39. Cobbs CS, Brenman JE, Aldape KD, Bredt DS, Israel MA. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 1995;55:727-30.
40. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S. Nitric oxide synthase activity in human breast cancer. Br J Cancer 1995;72:41-4.
41. Dueñas-Gonzalez A, Isales CM, del Mar Abad-Hernandez M, Gonzalez-Sarmiento MR, Sangueza O, Rodriguez-Commes J. Expression of inducible nitric oxide synthase in breast cancer correlates with metastatic disease. Mod Pathol 1997;10:645-9.
42. Thomsen LL, Miles DW. Role of nitric oxide in tumor progression: lessons from human tumors. Cancer Metast Rev 1998;17:107-18.
43. Klotz T, Bloch W, Volberg C, Engelmann U, Addicks K. Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 1998;82:1897-903.
44. Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA, Ziche M. Role of nitric oxide in angiogenesis and tumour progression in head and neck cancer. J Natl Cancer Inst 1998;90:587-96.
45. Fujimoto H, Ando Y, Yamashita T, Terazaki H, Tanaka Y, Sasaki J, Matsumoto M, Suga M, Ando M. Nitric oxide synthase activity in human lung cancer. Jpn J Cancer Res 1997;88:1190-8.
46. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 1997;236:54-8.
47. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, Ueki T, Hirano T, Yamamoto H, Fujimoto J, Okamoto E, Hayashi N, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 1998;27:951-8.
48. Bang YJ, Kwon JH, Kang SH, Kim JW, Yang YC. Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma. Biochem Biophys Res Commun 1998;8:43-7.
49. Ostrowski J, Trzeciak L, Kolodziejski J, Bomsztyk K. Increased constitutive activity of mitogen-activated protein kinase and renaturable 85 kDa kinase in human-colorectal cancer. Br J Cancer 1998;78:1301-6.
50. Specht MC, Barden CB, Fahey TJ. p44/p42-MAP kinase expression in papillary thyroid carcinomas. Surgery 2001;130:936-40.
51. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 1997;99:1478-83.